Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9375647 | 0.84 | CA2 (0.58) | CA2FFAR1DRD2 | |
| SCHEMBL1043747 | 0.84 | CA2 (0.47) | CA2FFAR1DRD2ALOX5HTR6 | |
| SCHEMBL1872709 | 0.84 | CA2 (0.47) | CA2FFAR1DRD2ALOX5HTR6 | |
| SCHEMBL6740016 | 0.82 | FFAR1 (0.51) | CA2FFAR1DRD2HTR6MTNR1A | |
| SCHEMBL7982000 | 0.82 | CA2 (0.55) | CA2L3MBTL1MAPK1MTNR1A | |
| SCHEMBL1545420 | 0.82 | CA2 (0.55) | CA2L3MBTL1MAPK1MTNR1A | |
| SCHEMBL2544576 | 0.82 | CA2 (0.55) | CA2L3MBTL1MAPK1MTNR1A | |
| SCHEMBL17272718 | 0.82 | CA2 (0.47) | CA2FFAR1DRD2ALOX5HTR6 | |
| SCHEMBL15865430 | 0.82 | CA2 (0.47) | CA2FFAR1DRD2ALOX5HTR6 | |
| SCHEMBL566659 | 0.80 | MEN1 (0.50) | CA2FFAR1HTR6L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035210-A9 | 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | ORION CORPORATION (FI) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035210-A9 | 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | PMP22, NPY2R, ADRA2C | CA2 624/4885FFAR1 1356/4885DRD2 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.